Oral Oncology
Volume 45, Issue 1 , Pages 63-68 , January 2009

The prognostic value of hypoxia markers in T2-staged oral tongue cancer

  • Jong-Lyel Roh

      Affiliations

    • Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, 388-1, Pungnap-dong, Songpa-gu, Seoul 138-736, Republic of Korea
    • ,
  • Kyung-Ja Cho

      Affiliations

    • Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
    • ,
  • Gui Young Kwon

      Affiliations

    • Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
    • ,
  • Chang Hwan Ryu

      Affiliations

    • Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, 388-1, Pungnap-dong, Songpa-gu, Seoul 138-736, Republic of Korea
    • ,
  • Hyo Won Chang

      Affiliations

    • Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, 388-1, Pungnap-dong, Songpa-gu, Seoul 138-736, Republic of Korea
    • ,
  • Seung-Ho Choi

      Affiliations

    • Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, 388-1, Pungnap-dong, Songpa-gu, Seoul 138-736, Republic of Korea
    • ,
  • Soon Yuhl Nam

      Affiliations

    • Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, 388-1, Pungnap-dong, Songpa-gu, Seoul 138-736, Republic of Korea
    • ,
  • Sang Yoon Kim

      Affiliations

    • Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, 388-1, Pungnap-dong, Songpa-gu, Seoul 138-736, Republic of Korea
    • Corresponding Author InformationCorresponding author. Tel.: +82 2 3010 3715; fax: +82 2 489 2773.

Received 3 February 2008 ,Revised 27 March 2008 ,Accepted 27 March 2008.

References 

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66
  2. Tankere F, Camproux A, Barry B, Guedon C, Depondt J, Gehanno P. Prognostic value of lymph node involvement in oral cancers: a study of 137 cases. Laryngoscope. 2000;110(12):2061–2065
  3. Kowalski LP, Bagietto R, Lara JR, Santos RL, Silva JF, Magrin J. Prognostic significance of the distribution of neck node metastasis from oral carcinoma. Head Neck. 2000;22(3):207–214
  4. Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK, Hoffman HT. Presentation, treatment, and outcome of oral cavity cancer: a national cancer data base report. Head Neck. 2002;24(2):165–180
  5. Woolgar JA, Rogers S, West CR, Errington RD, Brown JS, Vaughan ED. Survival and patterns of recurrence in 200 oral cancer patients treated by radical surgery and neck dissection. Oral Oncol. 1999;35(3):257–265
  6. Schliephake H. Prognostic relevance of molecular markers of oral cancer–a review. Int J Oral Maxillofac Surg. 2003;32(3):233–245
  7. Németh Z, Velich N, Bogdan S, Ujpál M, Szabó G, Suba ZS. The prognostic role of clinical, morphological and molecular markers in oral squamous cell tumors. Neoplasma. 2005;52(2):95–102
  8. Hoogsteen IJ, Marres HA, Bussink J, van der Kogel AJ, Kaanders JH. Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers: a review. Head Neck. 2007;29(6):591–604
  9. Janssen HL, Haustermans KM, Balm AJ, Begg AC. Hypoxia in head and neck cancer: how much, how important?. Head Neck. 2005;27(7):622–638
  10. Vaupel P, Mayer A, Höckel M. Tumor hypoxia and malignant progression. Methods Enzymol. 2004;381:335–354
  11. Yoshida K, Kashima K, Suenaga S, Nomi N, Shuto J, Suzuki M. Immunohistochemical detection of cervical lymph node micrometastases from T2N0 tongue cancer. Acta Otolaryngol. 2005;125(6):654–658
  12. Green FL, Page DL, Fleming ID, Fritz A, Balch CM. AJCC cancer staging manual. 6th ed.. New York: Springer-Verlag; 2002;
  13. Prince S, Bailey BM. Squamous carcinoma of the tongue: review. Brit J Oral Maxillofac Surg. 1999;37(3):164–174
  14. Sessions DG, Spector GJ, Lenox J, Haughey B, Chao C, Marks J. Analysis of treatment results for oral tongue cancer. Laryngoscope. 2002;112(4):616–625
  15. Kantola S, Parikka M, Jokinen K, Hyrynkangs K, Soini Y, Alho OP, et al. Prognostic factors in tongue cancer – relative importance of demographic, clinical and histopathological factors. Brit J Cancer. 2000;83(5):614–619
  16. O-charoenrat P, Pillai G, Patel S, Fisher C, Archer D, Eccles S, et al. Tumour thickness predicts cervical nodal metastases and survival in early oral tongue cancer. Oral Oncol. 2003;39(4):386–390
  17. Bova RJ, Quinn DI, Nankervis JS, Cole IE, Sheridan BF, Jensen MJ, et al. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res. 1999;5(10):2810–2819
  18. Lee JI, Soria JC, Hassan KA, El-Naggar AK, Tang X, Liu DD, et al. Loss of PTEN expression as a prognostic marker for tongue cancer. Arch Otolaryngol Head Neck Surg. 2001;127(12):1441–1445
  19. Xie X, Clausen OP, Boysen M. Prognostic significance of p21WAF1/CIP1 expression in tongue squamous cell carcinomas. Arch Otolaryngol Head Neck Surg. 2002;128(8):897–902
  20. Nagler RM, Kerner H, Laufer D, Ben-Eliezer S, Minkov I, Ben-Itzhak O. Squamous cell carcinoma of the tongue: the prevalence and prognostic roles of p53, Bcl-2, c-erbB-2 and apoptotic rate as related to clinical and pathological characteristics in a retrospective study. Cancer Lett. 2002;186(2):137–150
  21. Chuang HC, Su CY, Huang HY, Chien CY, Chen CM, Huang CC. High expression of CD105 as a prognostic predictor of early tongue cancer. Laryngoscope. 2006;116(7):1175–1179
  22. Lim SC, Zhang S, Ishii G, Endoh Y, Kodama K, Miyamoto S, et al. Predictive markers for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral tongue. Clin Cancer Res. 2004;10(1 Pt 1):166–172
  23. Myo K, Uzawa N, Miyamoto R, Sonoda I, Yuki Y, Amagasa T. Cyclin D1 gene numerical aberration is a predictive marker for occult cervical lymph node metastasis in TNM Stage I and II squamous cell carcinoma of the oral cavity. Cancer. 2005;104(12):2709–2716
  24. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997;38(2):285–289
  25. Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen FJ, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res. 2002;62(23):7066–7074
  26. Jonathan RA, Wijffels KI, Peeters W, de Wilde PC, Marres HA, Merkx MA, et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol. 2006;79(3):288–297
  27. Henke M, Mattern D, Pepe M, Bézay C, Weissenberger C, Werner M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol. 2006;24(29):4708–4713
  28. Rades D, Golke H, Schild SE, Kilic E. The impact of tumor expression of erythropoietin receptors and erythropoietin on clinical outcome of esophageal cancer patients treated with chemoradiation. Int J Radiat Oncol Biol Phys. 2008;71(1):152–159
  29. Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362(9392):1255–1260
  30. Machtay M, Pajak TF, Suntharalingam M, Shenouda G, Hershock D, Stripp DC, et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys. 2007;69(4):1008–1017
  31. Danish Head and Neck Cancer Group. Interim analysis of DAHANCA 10. <www.dahanca.dk/get_media_file.php?mediaid=125>; 2007 [accessed 01.03.07].

PII: S1368-8375(08)00100-0

doi: 10.1016/j.oraloncology.2008.03.017

Oral Oncology
Volume 45, Issue 1 , Pages 63-68 , January 2009

Article Tools

* Image Usage & Resolution